Management and Healthcare Utilization of Patients With Chronic Airway Disease During the COVID-19 Epidemic
- Conditions
- AsthmaPulmonary Disease, Chronic Obstructive
- Registration Number
- NCT04948216
- Lead Sponsor
- Peking University Third Hospital
- Brief Summary
During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the influencing factors during the COVID-19 epidemic.
- Detailed Description
During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the relevant factors during the COVID-19 epidemic. Using cross-sectional research methods, telephone interviews and questionnaire surveys were used to investigate the management and healthcare utilization of patients with chronic airway disease （COPD and asthma）during the COVID-19 epidemic.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 153
- COPD patients and asthma patients in the Chronic Airway Disease Database in Peking University Third Hospital.
- Refusal to participate in this study; cognitive dysfunction.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of exacerbation during the COVID-19 epidemic through study completion, an average of 2 week. Frequency of exacerbation during the COVID-19 epidemic
Respiratory symptoms through study completion, an average of 2 week. COPD Assessment Test (CAT)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking University Third Hospital
🇨🇳Beijing, Beijing, China